EP3419618A4 - CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING HEMATOLOGICAL MALIGNANT TUMORS, COMPOSITIONS AND METHODS FOR USING SAME - Google Patents

CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING HEMATOLOGICAL MALIGNANT TUMORS, COMPOSITIONS AND METHODS FOR USING SAME Download PDF

Info

Publication number: EP3419618A4
Authority: EP; European Patent Office
Prior art keywords: car; compositions; methods; same; antigen receptor
Prior art date: 2016-02-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP16891868.8A

Other languages

German (de)

French (fr)

Other versions

EP3419618A1 (en

Inventor

Yupo Ma

Kevin PINZ

Xun JIANG

Masayuki Wada

Kevin Chen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Icell Gene Therapeutics LLC

Original Assignee

Icell Gene Therapeutics LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-26

Filing date

2016-07-15

Publication date

2019-11-06

2016-02-26Priority claimed from PCT/US2016/019953external-prioritypatent/WO2016138491A1/en

2016-07-15Application filed by Icell Gene Therapeutics LLCfiledCriticalIcell Gene Therapeutics LLC

2019-01-02Publication of EP3419618A1publicationCriticalpatent/EP3419618A1/en

2019-11-06Publication of EP3419618A4publicationCriticalpatent/EP3419618A4/en

StatusWithdrawnlegal-statusCriticalCurrent

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EP16891868.8A2016-02-262016-07-15 CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING HEMATOLOGICAL MALIGNANT TUMORS, COMPOSITIONS AND METHODS FOR USING SAMEWithdrawnEP3419618A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/US2016/019953WO2016138491A1 (en)	2015-02-27	2016-02-26	Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
PCT/US2016/042591WO2017146767A1 (en)	2015-02-27	2016-07-15	Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof

Publications (2)

Publication Number	Publication Date
EP3419618A1 EP3419618A1 (en)	2019-01-02
EP3419618A4true EP3419618A4 (en)	2019-11-06

Family

ID=64565015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16891868.8AWithdrawnEP3419618A4 (en)	2016-02-26	2016-07-15	CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING HEMATOLOGICAL MALIGNANT TUMORS, COMPOSITIONS AND METHODS FOR USING SAME

Country Status (1)

Country	Link
EP (1)	EP3419618A4 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020009449A1 (en)*	1991-10-07	2002-01-24	Biogen, Inc., A Massachusetts Corporation	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US20040265315A1 (en)*	2002-09-05	2004-12-30	Christine Dingivan	Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US20120134970A1 (en)*	2009-01-23	2012-05-31	Wen Yang	Viral Vectors Encoding Multiple Highly Homologus Non-Viral Polypeptides And The Use Of Same
US20150038684A1 (en)*	2012-02-13	2015-02-05	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2016138491A1 (en)*	2015-02-27	2016-09-01	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof

2016
- 2016-07-15EPEP16891868.8Apatent/EP3419618A4/ennot_activeWithdrawn

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020009449A1 (en)*	1991-10-07	2002-01-24	Biogen, Inc., A Massachusetts Corporation	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US20040265315A1 (en)*	2002-09-05	2004-12-30	Christine Dingivan	Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US20120134970A1 (en)*	2009-01-23	2012-05-31	Wen Yang	Viral Vectors Encoding Multiple Highly Homologus Non-Viral Polypeptides And The Use Of Same
US20150038684A1 (en)*	2012-02-13	2015-02-05	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2016138491A1 (en)*	2015-02-27	2016-09-01	Icell Gene Therapeutics Llc	Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
E J CHEADLE ET AL: "Ligation of the CD2 co-stimulatory receptor enhances IL-2 production from first-generation chimeric antigen receptor T cells", GENE THERAPY, vol. 19, no. 11, 1 December 2011 (2011-12-01), pages 1114 - 1120, XP055122891, ISSN: 0969-7128, DOI: 10.1038/gt.2011.192*
JIA-HUAI WANG ET AL: "Structure of a Heterophilic Adhesion Complex between the Human CD2 and CD58 (LFA-3) Counterreceptors", CELL, vol. 97, no. 6, 11 June 1999 (1999-06-11), AMSTERDAM, NL, pages 791 - 803, XP055627194, ISSN: 0092-8674, DOI: 10.1016/S0092-8674(00)80790-4*
See also references ofWO2017146767A1*

Also Published As

Publication number	Publication date
EP3419618A1 (en)	2019-01-02

Publication	Publication Date	Title
PH12019500193A1 (en)	2019-07-29	Chimeric antigen receptors targeting bcma and methods of use thereof
IL276396B1 (en)	2025-09-01	Chimeric antigen receptors targeting cd70
SG11202003258QA (en)	2020-05-28	Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereof
EP3474867A4 (en)	2020-05-20	CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS
IL265755A (en)	2019-06-30	Chimeric antigen receptors for the treatment of cancer
SA517381703B1 (en)	2021-05-23	Anti-C10orf54 Antibodies And Uses Thereof
PH12018500815A1 (en)	2018-10-01	Antibody conjugates comprising toll-like receptor agonist
IL250339A0 (en)	2017-03-30	Egfrviii specific chimeric antigen receptors for cancer immunotherapy
EP3436070A4 (en)	2019-11-27	CHIMERIC ANTIGENIC RECEPTORS TARGETING CANCER
IL250831A0 (en)	2017-04-30	Antibodies and chimeric antigen receptors specific for cd19, preparations containing them and their uses
SI3925952T1 (en)	2024-03-29	PROSTATE-SPECIFIC, MEMBRANE ANTIGEN-TARGETED HIGH-AFFINITY AGENTS FOR PROSTATE CANCER ENDORADIOTHERAPY
PH12016502369A1 (en)	2017-02-20	Tri-specific binding molecules and methods of use thereof
EP3130608A4 (en)	2017-09-13	(anti-her2 antibody)-drug conjugate
EP3373970A4 (en)	2019-07-10	NKG2D-IG FUSION PROTEIN FOR IMMUNOTHERAPY AGAINST CANCER
LT3183268T (en)	2020-06-10	ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR (CAR) FOR THE TREATMENT OF CANCER
PH12016502061A1 (en)	2016-12-19	Novel antii-rnf43 antibodies and methods of use
EP3271401A4 (en)	2018-11-21	Conjugates for the treatment of cancer targeted at intracellular tumor-associated antigens
EP3352800A4 (en)	2019-03-27	METHODS AND COMPOSITIONS FOR REDUCING METASTASES
EP3347053A4 (en)	2019-04-17	FUNCTIONAL, SEGREGATED, CHARGED AND NANOSUPPORTED TELODENDRIMERS, METHODS FOR PREPARING AND USING SAME
EA201171063A1 (en)	2012-01-30	PHARMACEUTICAL COMPOSITIONS OF OLMESARTAN
MA43378A (en)	2018-10-10	COMPOSITIONS AND METHODS FOR REDUCTION OF IMMUNE RESPONSE AGAINST CHEMERIC ANTIGEN RECEPTORS
EP3347098A4 (en)	2019-06-26	TARGETING MDA-5 ACTIVATION FOR CANCER IMMUNOTHERAPY
MX2019004434A (en)	2019-09-26	Anti-edb antibodies and antibody-drug conjugates.
EP2991687A4 (en)	2016-11-09	PROSTHETIC COMPOUNDS FOR MARKING INTERNALIZATION BIOMOLECULES
EP3630172A4 (en)	2020-06-03	COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY AND IMMUNOTHERAPY INVOLVING HER ANTIGENS

Legal Events

Date	Code	Title	Description
2017-09-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text:STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-11-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text:ORIGINAL CODE: 0009012
2018-11-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text:STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-01-02	17P	Request for examination filed	Effective date:20180926
2019-01-02	AK	Designated contracting states	Kind code of ref document:A1 Designated state(s):AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-01-02	AX	Request for extension of the european patent	Extension state:BA ME
2019-06-05	DAV	Request for validation of the european patent (deleted)
2019-06-05	DAX	Request for extension of the european patent (deleted)
2019-11-06	A4	Supplementary search report drawn up and despatched	Effective date:20191009
2019-11-06	RIC1	Information provided on ipc code assigned before grant	Ipc:C07K 16/28 20060101ALI20191002BHEP Ipc:A61K 39/00 20060101ALI20191002BHEP Ipc:A61P 35/00 20060101ALI20191002BHEP Ipc:A61K 38/00 20060101ALI20191002BHEP Ipc:A61K 31/519 20060101ALI20191002BHEP Ipc:A61K 39/39 20060101ALI20191002BHEP Ipc:A61K 31/405 20060101ALI20191002BHEP Ipc:C07K 14/705 20060101AFI20191002BHEP Ipc:C07K 16/46 20060101ALI20191002BHEP Ipc:A61K 48/00 20060101ALI20191002BHEP Ipc:C07K 14/725 20060101ALI20191002BHEP
2020-10-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text:STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-11-11	18D	Application deemed to be withdrawn	Effective date:20200603

Movatterモバイル変換